Health
Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers – OncLive
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant…
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib (AMG 510) and adagrasib in preclinical models, according to findings presented during Week 1 of the 2021 AACR Virtual Annual Meeting.1,2
The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases…
-
General20 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
General10 hours agoMan dies in daylight shooting in Sydney’s north-west
-
Noosa News19 hours agoCouncil steps up staff protection after surge in abuse
-
Noosa News13 hours agoResident rushed to hospital with multiple burns as house engulfed in flames in Woodridge